- Home
- RGLD vs MRNA Comparison
RGLD vs MRNA Comparison
Compare RGLD & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGLD
- MRNA
- Stock Information
- Founded
- RGLD 1981
- MRNA 2010
- Country
- RGLD United States
- MRNA United States
- Employees
- RGLD N/A
- MRNA N/A
- Industry
- RGLD Precious Metals
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RGLD Industrials
- MRNA Health Care
- Exchange
- RGLD Nasdaq
- MRNA Nasdaq
- Market Cap
- RGLD 12.3B
- MRNA 10.3B
- IPO Year
- RGLD N/A
- MRNA 2018
- Fundamental
- Price
- RGLD $182.85
- MRNA $25.50
- Analyst Decision
- RGLD Buy
- MRNA Hold
- Analyst Count
- RGLD 8
- MRNA 19
- Target Price
- RGLD $181.25
- MRNA $48.13
- AVG Volume (30 Days)
- RGLD 577.9K
- MRNA 10.9M
- Earning Date
- RGLD 08-06-2025
- MRNA 07-31-2025
- Dividend Yield
- RGLD 1.00%
- MRNA N/A
- EPS Growth
- RGLD 78.68
- MRNA N/A
- EPS
- RGLD 6.04
- MRNA N/A
- Revenue
- RGLD $756,995,000.00
- MRNA $3,177,000,000.00
- Revenue This Year
- RGLD $25.64
- MRNA N/A
- Revenue Next Year
- RGLD $16.91
- MRNA $9.87
- P/E Ratio
- RGLD $29.70
- MRNA N/A
- Revenue Growth
- RGLD 31.09
- MRNA N/A
- 52 Week Low
- RGLD $122.17
- MRNA $23.15
- 52 Week High
- RGLD $191.78
- MRNA $138.07
- Technical
- Relative Strength Index (RSI)
- RGLD 57.88
- MRNA 43.68
- Support Level
- RGLD $177.86
- MRNA $25.06
- Resistance Level
- RGLD $183.48
- MRNA $26.02
- Average True Range (ATR)
- RGLD 3.99
- MRNA 1.14
- MACD
- RGLD 0.11
- MRNA -0.20
- Stochastic Oscillator
- RGLD 76.78
- MRNA 8.47
About RGLD Royal Gold Inc.
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.